Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 17290721)

1.

Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F.

Mayo Clin Proc. 2007 Feb;82(2):159-65. Review.

PMID:
17290721
2.

Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.

Persson M, Hedblad B, Nelson JJ, Berglund G.

Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1411-6. Epub 2007 Apr 12.

3.

Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.

Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S.

Eur Heart J. 2009 Jan;30(1):107-15. doi: 10.1093/eurheartj/ehn502. Epub 2008 Nov 19.

4.

The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.

Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH.

J Vasc Surg. 2007 Sep;46(3):500-6. Epub 2007 Jul 30.

5.

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1788-95. Epub 2007 May 31.

6.

Lipoprotein-associated phospholipase A2.

McConnell JP, Hoefner DM.

Clin Lab Med. 2006 Sep;26(3):679-97, vii. Review.

PMID:
16938590
7.
9.
10.

[Lipoprotein-associated phospholipase A2 serum levels in patients from different categories of cardiovascular risk].

Nozadze DN, Sergienko IV, Balakhonova TV, Semenova AE, Vlasik TN, Kukharchuk VV.

Kardiologiia. 2014;54(3):57-63. Russian.

PMID:
25102750
11.

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.

Carlquist JF, Muhlestein JB, Anderson JL.

Expert Rev Mol Diagn. 2007 Sep;7(5):511-7. Review.

PMID:
17892360
12.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
14.

Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.

Vittos O, Toana B, Vittos A, Moldoveanu E.

Biomarkers. 2012 Jun;17(4):289-302. doi: 10.3109/1354750X.2012.664170. Epub 2012 Mar 9. Review.

PMID:
22401038
15.

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E.

Arch Intern Med. 2005 Nov 28;165(21):2479-84.

PMID:
16314544
16.

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.

Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP.

Prev Cardiol. 2006 Summer;9(3):138-43. Review.

PMID:
16849876
17.

PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.

Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, Sofat R, Nicolaides AN, Corsetti JP, Fowkes FG, Tzoulaki I, Kumari M, Brunner EJ, Kivimaki M, Marmot MG, Hoffmann MM, Winkler K, März W, Ye S, Stirnadel HA, Boekholdt SM, Khaw KT, Humphries SE, Sandhu MS, Hingorani AD, Talmud PJ.

Circulation. 2010 Jun 1;121(21):2284-93. doi: 10.1161/CIRCULATIONAHA.109.923383. Epub 2010 May 17. Erratum in: Circulation. 2010 Jul 20;122(3):e400. Boekholdt, S Matthijs [added].

18.

Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.

Theocharidou E, Tellis CC, Mavroudi M, Soufleris K, Gossios TD, Giouleme O, Athyros VG, Tselepis AD, Karagiannis A.

J Crohns Colitis. 2014 Sep;8(9):936-44. doi: 10.1016/j.crohns.2014.01.016. Epub 2014 Feb 12.

PMID:
24529818
19.

Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.

Li N, Li S, Yu C, Gu S.

Postgrad Med. 2010 Jul;122(4):200-5. doi: 10.3810/pgm.2010.07.2187.

PMID:
20675983
20.

Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.

Charniot JC, Khani-Bittar R, Albertini JP, Giral P, Cherfils C, Cosson C, Guillerm E, Leprince P, Gandjbakhch I, Bonnefont-Rousselot D.

Int J Cardiol. 2013 Sep 20;168(1):132-8. doi: 10.1016/j.ijcard.2012.09.054. Epub 2012 Oct 24.

PMID:
23103135
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk